Article

Changes in Cancer Mortality among HIV-Infected Patients: The Mortalite 2005 Survey

Institut National de la Santé et de la Recherche Médicale (Inserm), U593, Bordeaux, France.
Clinical Infectious Diseases (Impact Factor: 9.42). 04/2009; 48(5):633-9. DOI: 10.1086/596766
Source: PubMed

ABSTRACT The goal of the current study was to describe the distribution and characteristics of malignancy related deaths among human immunodeficiency virus (HIV)-infected patients with use of data obtained from a national survey conducted in France in 2005 and to compare with results obtained from a similar survey conducted in 2000.
The underlying cause of death was documented using a standardized questionnaire fulfilled in French hospital wards and networks that were involved in the treatment of HIV-infected patients.
Among the 1042 deaths reported in 2005 (964 were reported in 2000), 344 were cancer related (34%), which represented a significant increase from 2000 (29% of deaths were cancer related) (P=.02); 134 of the cancer-related deaths were AIDS related and 210 were not AIDS related. Among the cancer-related causes of death, the proportion of hepatitis-related cancers (6% in 2000 vs. 11% in 2005) and non-AIDS/hepatitis-related cancers (38% in 2000 vs 50% in 2005) significantly increased from 2000 to 2005 (P=.03 and P=.01, respectively), compared with the proportion of cancer that was AIDS related and adjusting for age and sex. Among cases involving AIDS, the proportion of non-Hodgkin lymphoma-associated deaths did not change statistically significantly between 2000 and 2005 (11% and 10% of deaths, respectively).
In this study, an increasing proportion of lethal non-AIDS-related cancers was demonstrated from 2000 to 2005; meanwhile, the proportion of lethal AIDS-related cancers remained stable among HIV-infected patients. Thus, cancer prophylaxis, early diagnosis, and improved management should be included in the routine long-term follow-up of HIV-infected patients.

0 Followers
 · 
124 Views
  • Source
    • "The availability of highly active antiretroviral therapy (HAART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of HAART on HIV-related mortality, malignancies remain an important cause of death in the current era [1] [2]. The use of HAART was also associated with reduced incidence of the two major AIDS-associated malignancies—Kaposi's sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL) [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hodgkin lymphoma (HL) represents one of the most common non-AIDS-defining cancers with an increasing incidence overtime. Clinically, patients present advanced stages of disease with extranodal involvement in the majority of cases. In the last years, significant improvements in the treatment of patients with HL and HIV infection have been achieved. In the lack of randomized trials, several phase II studies have showed that in the era of highly active antiretroviral therapy (HAART) the same regimens employed in HIV-negative patients with HL can be used in HIV setting with similar results. Moreover, in the last years the feasibility of high dose chemotherapy and peripheral stem cell rescue has allowed to save those patients who failed the upfront treatment. Finally, in the near future, a better integration of diagnostic tools (including PET scan), chemotherapy (including new drugs), radiotherapy, HAART, and supportive care will significantly improve the outcome of these patients.
    Advances in Hematology 01/2011; 2011. DOI:10.1155/2011/402682
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since 1996, the availability of highly active antiretroviral therapy (HAART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of HAART on HIV-related mortality, malignancies remain an important cause of death in the current era (Clin Infect Dis 48(5):633–639, 2009; Clin Infect Dis 49(3):481–482, 2009). The use of HAART was also associated with reduced incidence of the two major AIDS-associated malignancies – Kaposi’s sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL) (AIDS 20:1645–1654, 2006). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and hepatocarcinoma has been observed recently (Blood 108:3786–3791, 2006).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Gilbert channel is a model for representing a multipath fading channel for multicarrier transmission using various parameters, such as the steady state probabilities, power ratio between each state and so on. However, a method to set parameters has not been studied. The validity of this channel model has also not been confirmed. Moreover, this channel modeling considering the effect of the non-linear amplifier has not been investigated. In this paper, we propose a more detailed Gilbert channel, including the effect of the non-linear amplifier, and a method to set parameters of the Gilbert channel. We also compare the error performance between the Gilbert channel and multipath fading channel on a convolutional coded multicarrier modulation (MCM) system. Numerical results show that our proposed channel model can approximately express the multipath fading channel
    Electrical and Electronic Technology, 2001. TENCON. Proceedings of IEEE Region 10 International Conference on; 02/2001
Show more